11 citations
,
December 2018 in “Assay and Drug Development Technologies”
Natural herbal compounds might treat certain medical conditions by reducing DHT levels, but more research is needed to confirm their effectiveness and safety.
The conversation discusses the need for a localized 5-alphareductaseinhibitor that only affects the scalp without systemic side effects, similar to pyrilutamide's approach. Current treatments like topical liposomal finasteride and dutasteride are mentioned, but concerns about their systemic effects and lack of research are highlighted.
Finasteride and dutasteride are discussed for hair loss, with concerns about their effects on neurosteroids and potential side effects like depression. Alternatives like topical estrogen and lifestyle changes are considered, with varying opinions on mental health and hair regrowth.
FCE 28260 (PNU 156765), an under-explored 5α-reductaseinhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
Avixis Alfatradiol is a topical5-alphareductaseinhibitor available in Latin America and Germany, but its effectiveness is questioned. A user reported worsened hair loss after using it and recommended finasteride instead due to its proven effectiveness and lower cost.
GHK-Cu is a potent inhibitor of the type 1 5-alphareductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alphareductaseinhibitors. The user previously experienced side effects with 5-alphareductaseinhibitors and is considering GHK-Cu as an alternative.